Correction to: Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
Crossref DOI link: https://doi.org/10.1007/s13300-021-01123-w
Published Online: 2021-09-13
Published Print: 2021-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Seino, Hiroaki http://orcid.org/0000-0003-4690-9722
Text and Data Mining valid from 2021-09-13
Version of Record valid from 2021-09-13
Article History
First Online: 13 September 2021